Your browser doesn't support javascript.
loading
Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.
de Kock, M; Tarning, J; Workman, L; Nyunt, M M; Adam, I; Barnes, K I; Denti, P.
Afiliación
  • de Kock M; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Tarning J; World Wide Antimalarial Resistance Network (WWARN), Oxford, UK.
  • Workman L; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Nyunt MM; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Adam I; World Wide Antimalarial Resistance Network (WWARN), Oxford, UK.
  • Barnes KI; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Denti P; World Wide Antimalarial Resistance Network (WWARN), Oxford, UK.
CPT Pharmacometrics Syst Pharmacol ; 6(7): 430-438, 2017 07.
Article en En | MEDLINE | ID: mdl-28597978
Sulfadoxine/pyrimethamine is recommended for intermittent preventative treatment of malaria during pregnancy. Data from 98 women during pregnancy and 77 after delivery in four African countries were analyzed using nonlinear mixed-effects modeling to characterize the effects of pregnancy, postpartum duration, and other covariates such as body weight and hematocrit on sulfadoxine/pyrimethamine pharmacokinetic properties. During pregnancy, clearance increased 3-fold for sulfadoxine but decreased by 18% for pyrimethamine. Postpartum sulfadoxine clearance decreased gradually over 13 weeks. This finding, together with hematocrit-based scaling of plasma to whole-blood concentrations and allometric scaling of pharmacokinetics parameters with body weight, enabled site-specific differences in the pharmacokinetic profiles to be reduced significantly but not eliminated. Further research is necessary to explain residual site-specific differences and elucidate whether dose-optimization, to address the 3-fold increase in clearance of sulfadoxine in pregnant women, is necessary, viable, and safe with the current fixed dose combination of sulfadoxine/pyrimethamine.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimetamina / Sulfadoxina / Modelos Biológicos / Antimaláricos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Pregnancy País/Región como asunto: Africa Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimetamina / Sulfadoxina / Modelos Biológicos / Antimaláricos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Pregnancy País/Región como asunto: Africa Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Estados Unidos